An observational study in Septic Shock, sponsored by Assiut University. Not yet recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-07.
Sponsored by Assiut University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Shock, Septic by Assiut University — 11 open to participants now, 11 under way, none of them phase 3. Shock, Septic · Assiut University.
Among the 16 studies in Shock, Septic by Assiut University, this one is the 4th largest by planned enrollment of the 14 observational ones that give a count, is one of 6 that started in 2026, is one of 14 observational ones, reaches primary completion later than 4 of the 10 other live ones, and was the 11th registered.
1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.
Browse Shock, Septic studies →11 of the 16 studies in Shock, Septic by Assiut University are open now, in 1 country. Recruiting first, the newest first:
Assiut University
Ages 18–65
Assiut University
Ages 18+
Assiut University
Ages 18+
Assiut University · Sites in Egypt
Ages 18+
Assiut University
Ages 18+
By country, each count listing its studies:
Of the 137 Shock, Septic studies recruiting now, 103 (75%) set no upper age limit and 18 (13%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2019; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is close to the median of 108 across 408 observational studies indexed under Shock, Septic.
Median enrollment 68 across the 2 interventional studies, 87 across the 14 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assiut University is the lead sponsor of 5,094 studies on the registry; 2,187 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
6 of the studies in Shock, Septic by Assiut University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07245550Assiut UniversityThyroid and Adrenal Disorders in ICU | 2026-12-01 |
| NCT07321405Assiut UniversityAssessment of Cardiac Output and Stroke Volume in Septic Shock Patients | 2027-07-01 |
| NCT07698834Assiut UniversitySplanchnic Perfusion Monitoring in Septic Shock Using Doppler Ultrasound | 2027-09 |
| NCT07812051Assiut UniversityIonized Calcium as a Severity Marker in Septic Shock Patients | 2027-10 |
| NCT07888036Assiut UniversityNeutrophil Activation and NETosis in Sepsis | 2027-10-20 |
Add all 6 to your calendar (.ics) → With an account.
Among the 16 studies in Shock, Septic by Assiut University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this research is to compare the accuracy and reliability of electrical cardiometry versus transthoracic echocardiography in measuring cardiac output and stroke volume in patients with septic shock, to evaluate the potential of EC as a non-invasive alternative for hemodynamic monitoring.
Sepsis is a life-threatening condition caused by a dysregulated immune response to infection, leading to organ dysfunction. It remains a leading global cause of morbidity and mortality, often progressing rapidly to septic shock and multi-organ failure if not promptly diagnosed and treated.
The complex pathophysiology involves systemic inflammation, endothelial damage, and impaired tissue perfusion, making early recognition and hemodynamic stabilization vital for survival. Accurate monitoring of cardiac function plays a key role in managing septic patients.
Cardiac output (CO) and stroke volume (SV) are key hemodynamic parameters guiding therapy in critically ill patients, particularly those with pneumonia and septic shock, who experience severe circulatory and respiratory dysfunction contributing to their high mortality.
Transthoracic echocardiography (TTE) is the gold standard for non-invasive bedside assessment of CO and SV, providing precise evaluation of cardiac structure and flow. However, TTE requires operator expertise, can be time-consuming, and may be limited by patient-specific factors.
Electrical cardiometry (EC) is an emerging non-invasive bio-impedance technique offering continuous monitoring with easier application and less operator dependency. Despite its advantages, EC's accuracy and reliability in critically ill septic patients require further validation.
Currently, hemodynamic monitoring mainly relies on clinical assessment combined with intermittent TTE, with invasive methods reserved for selective cases; EC holds potential as a simpler, safer alternative warranting further investigation.
patients were aged more than 18 years diagnosed with septic shock following the surviving sepsis campaign
-
Inclusion Criteria: patients aged more than 18 years must be diagnosed with septic shock following the surviving sepsis campaign
-
Exclusion Criteria:
echocardiography and electrical cardiometry will be applied to these patients
Device: echocardiogram · Device: Electrical cardiometry
Transthoracic echocardiography (TTE) is the gold standard for non-invasive bedside assessment of CO and SV, providing precise evaluation of cardiac structure and flow. However, TTE requires operator expertise, can be time-consuming, and may be limited by patient-specific factors.
Electrical cardiometry (EC) is an emerging non-invasive bio-impedance technique offering continuous monitoring with easier application and less operator dependency. Despite its advantages, EC's accuracy and reliability in critically ill septic patients require further validation.
to compare the accuracy and reliability of electrical cardiometry versus transthoracic echocardiography in measuring cardiac output in patients with septic shock.
to compare the accuracy and reliability of electrical cardiometry versus transthoracic echocardiography in measuring cardiac output in patients with septic shock.
Time frame: 2026-2028
cardiac output and stroke volume in septic shock patients
comparison between accuracy and reliability in assessment of cardiac out put and stroke volume using echocardiogram vs electrical cardiometer
Time frame: baseline
to compare the accuracy and reliability of electrical cardiometry versus transthoracic echocardiography in measuring stroke volume in patients with septic shock.
to compare the accuracy and reliability of electrical cardiometry versus transthoracic echocardiography in measuring stroke volume in patients with septic shock.
Time frame: 2026-2028
Plan to share: Undecided
Start is estimated for Apr 2026; primary completion for Jul 2027, 15 months later.
Of 189 non-industry observational studies under Shock, Septic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 47. This study's planned 15 months is below that.
Counting every sponsor, half of 202 studies reached it within 25 months; a quarter within 12 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.